Chemicon International and Stem Cell Sciences Announce Launch of ESGRO Complete(TM) Product Line
2006年3月1日 - 12:00AM
ビジãƒã‚¹ãƒ¯ã‚¤ãƒ¤ï¼ˆè‹±èªžï¼‰
New Grade of Serum and Feeder-Free Media for Mouse Embryonic Stem
Cell Expansion Serologicals Corporation (NASDAQ: SERO) announced
today that Chemicon International, Inc., its wholly-owned
subsidiary, and Stem Cell Sciences plc (LSE:STEM, SCS) are
launching the ESGRO Complete(TM) product line for murine embryonic
stem (ES) cell culture, following the establishment of an exclusive
agreement on November 3, 2005. Chemicon will exclusively market the
licensed ESGRO Complete(TM) Clonal Grade Medium for serum-free,
feeder-free expansion of mouse ES cells. The product, developed by
SCS's SC Proven division, is the first complete, defined medium
that enables the large-scale, consistent production of mouse ES
cells for the use in world-wide research and drug discovery
markets. To complement the offering, Chemicon will be releasing
other media and reagents needed for routine mouse ES cell culture
that have been specifically engineered and validated for use in
this serum-free system. The ESGRO Complete(TM) product line will
broaden Chemicon's offering within the stem cell culture market and
will complement the current portfolio of innovative reagents and
technologies that are already being supplied to its customer base.
"The ESGRO Complete(TM) product line is a great leap forward over
the existing methodologies used by stem cell researchers today,"
said Jeffrey D. Linton, President of Chemicon and Upstate,
Serologicals' Research Segment companies. "This is a culmination of
our earlier agreement with Stem Cell Sciences to commercialize this
technology through our Research segment, and is yet another example
of how Chemicon is establishing itself as a leading company in the
stem cell research arena." "We are very excited about the launch of
our first cell culture media product. This will generate revenue
streams in the near term and marks a major milestone in our
development," said Peter Mountford, CEO of Stem Cell Sciences plc.
"The launch validates our technology and will contribute to the
wider adoption of stem cells within the global drug discovery
market. We look forward to our continued collaboration with
Chemicon and the opportunity to expand the stem cell culture
product offering in due course." Chemicon International, Inc.
offers a broad range of research products, including specialty
reagents, kits, antibodies, and custom products and services, to
customers working in the areas of neuroscience, stem cell biology,
cancer, and infectious disease research. It is also a leading
supplier of monoclonal antibodies, conjugates, antibody blends and
molecular-based detection kits for use in diagnostic laboratories.
Chemicon focuses on basic and biomedical research, drug discovery,
and diagnostics, allowing it to serve thousands of customers
worldwide in the academic, clinical, biotechnology, and
pharmaceutical sectors. Acquired in 2003, Chemicon is a
Serologicals company, based in Temecula, CA. For more information,
please visit our website: www.chemicon.com. Serologicals
Corporation (NASDAQ: SERO), headquartered in Atlanta, GA, is a
global leader in developing and commercializing consumable
biological products, enabling technologies and services in support
of biological research, drug discovery, and the bioprocessing of
life-enhancing products. Our customers include researchers at major
life science companies and leading research institutions involved
in key disciplines, such as neurology, oncology, hematology,
immunology, cardiology, proteomics, infectious diseases, cell
signaling and stem cell research. In addition, Serologicals is the
world's leading provider of monoclonal antibodies for the blood
typing industry. Serologicals employs a total of more than 1,000
people worldwide in three Serologicals' companies: Chemicon
International, headquartered in Temecula, CA, Upstate Group, LLC,
headquartered in Charlottesville, VA, and Celliance Corporation,
headquartered in Atlanta, GA. For more information, please visit
our website: www.serologicals.com. Stem Cell Sciences plc (SCS) is
a global biotechnology company focused on the development of stem
cell technologies. The Company has established a leading
intellectual property (IP) and technology portfolio that enables
the commercial application of stem cells in pharmaceutical and
biotechnology drug discovery, providing the Company with an
early-stage revenue stream. In the longer term, the Company is
developing regenerative, cell-based therapies. Stem Cell Sciences
has four business units focused on key sustainable business
strategies. SC Proven provides serum free, cell culture media and
reagents that enable the growth of stem cells. The first
commercially available product, a mouse embryonic stem cell growth
medium, has been exclusively licensed for manufacture and marketing
to Chemicon, a division of Serologicals Inc. SC Licensing licenses
its proprietary technologies such as Internal Ribosome Entry Site
(IRES) and Stem Cell Selection for application in laboratory-based
research and discovery. SC Services will provide cell production
for research and high-throughput drug screening. SC Therapies first
program is being undertaken by SCS's Japanese affiliate, which
recently announced the exclusive licensing of human multipotent
adipocyte-derived (hMads) for use in an experimental cell based
therapy programme against Duchenne's Muscular Dystrophy that will
form the basis for a degenerative diseases focused pre-clinical
programme. SCS plc is a global Group with operations in the UK,
Australia and Japan. Each company is affiliated with academic stem
cell centers of excellence in order to access and commercialize new
IP developing in the field. These include the Institute of Stem
Cell Research, Edinburgh, UK; RIKEN Centre for Development Biology,
Japan and the Australian Stem Cell Centre, Melbourne, Australia.
SCS, which listed on the London Alternative Investment Market in
July 2005, was founded in 1994 to commercialize findings from the
Institute of Stem Cell Research at the University of Edinburgh, UK,
and Monash University, Melbourne, Australia. The Company is a
participant in two research projects under the European Union's
Framework Six Programme for Research and Technology Development and
is a contributor to the UK Stem Cells Initiative. For further
information please visit the corporate website at:
http://www.stemcellsciences.com/. This release contains certain
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Words or phrases such as
"should result," "are expected to," "we anticipate," "we estimate,"
"we project" or similar expressions are intended to identify
forward-looking statements. These statements are subject to certain
risks and uncertainties that could cause actual results to differ
materially from those expressed in any forward-looking statements.
You should not place undue reliance on forward-looking statements,
since the statements speak only as of the date that they are made,
and the Company undertakes no obligation to update these statements
based on events that may occur after the date of this press
release. Serologicals is a registered trademark of Serologicals
Royalty Company.
Serologicals (NASDAQ:SERO)
éŽåŽ» æ ªä¾¡ãƒãƒ£ãƒ¼ãƒˆ
ã‹ã‚‰ 5 2024 ã¾ã§ 6 2024
Serologicals (NASDAQ:SERO)
éŽåŽ» æ ªä¾¡ãƒãƒ£ãƒ¼ãƒˆ
ã‹ã‚‰ 6 2023 ã¾ã§ 6 2024